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Abstract
Background: The aim of the study was to assess long-term incidence of atrial fibrillation 
(AF) in cardiac resynchronization (CRT) recipients with and without prior arrhythmic history, 
factors predisposing to arrhythmia, as well as to evaluate the prognostic power of cumulative 
arrhythmia burden, duration of the longest episode and the number of episodes.
Methods: Device-collected data on AF episodes during 24 months in 96 participants of  
a randomized CRT-trial were analyzed (15% in NYHA class IV, sinus rhythm, median left 
ventricular ejection fraction 24% and QRS 169 ms). Blindly adjudicated major adverse car-
diac events (MACE) and any-cause death were censoring variables.
Results: Two-year incidence of AF was 70%, including 66% of patients without previous AF 
history. No baseline characteristics distinguished those who developed new onset AF. Percent of 
time spent in AF, but not number of episodes predicted mortality (adjusted hazard ratio [HR] 
1.05 ± 95% confidence interval CI 1.01–1.10) and MACE incidence (HR 1.03 ± 1.01–1.07; 
p = 0.03). Duration of the longest episode also predicted mortality (HR 1.06 ± 1.01–1.12; both 
p = 0.03). Prognostic impact of AF load was marked only in patients with slower ventricular 
response (< 98/min), but was independent from CHADS2 scores, pacing burden, or prior 
atrioventricular nodal ablation.
Conclusions: Seven out of 10 CRT-patients had AF within 2 years, including two-thirds of 
subjects without arrhythmic history. No baseline features distinguished those who developed 
new onset AF. Arrhythmia burden and duration of the longest episode, but not number of 
episodes influenced outcomes in CRT-patients, irrespectively from pacing burden or prior 
atrioventricular node ablation. (Cardiol J 2015; 22, 3: 267–275)
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Introduction
Atrial fibrillation (AF) carries an ominous 
prognosis in patients undergoing cardiac resyn-
chronization therapy (CRT) [1–3]. Early studies 
used ambulatory electrocardiogram (ECG) or 
Holter recordings to detect AF [4]. Thus, many 
short, asymptomatic AF episodes may have been 
missed. Modern implantable devices are capable 
of detecting any, even short-lasting AF episodes 
and can store numerous arrhythmia-related param-
eters, like its cumulative load, number of episodes, 
or ventricular response. Although it has been sug-
gested, that CRT can reduce AF incidence, data on 
its exact incidence, burden and predisposing factors 
are still scarce in patients undergoing biventricular 
pacing [5]. What is more, it is still a subject of con-
troversy which parameters: cumulative time spent 
in arrhythmia, episode duration or the number of 
AF episodes have the prognostic significance.
The aim of our study was to assess a 2-year 
arrhythmia incidence in CRT recipients with and 
without prior AF history and to identify factors 
predisposing to this arrhythmia. We aimed also at 
evaluating the prognostic power of cumulative AF 




Triple-Site Versus Standard Cardiac Resyn-
chronization Therapy (TRUST CRT) was a single 
center, prospective, randomized trial to assess 
the effectiveness of triple-site pacing vs. standard 
cardiac resynchronization. The study protocol and 
procedural outcomes have been published previ-
ously [6, 7]. The study included patients with symp-
tomatic heart failure in New York Heart Association 
(NYHA) functional class III–IV despite optimal 
medical treatment, with QRS width ≥ 120 ms, 
left ventricular ejection fraction (LVEF) £ 35% 
and significant (≥ 40 ms) inter- or intra-ventricular 
mechanical dyssynchrony. Patients had to be in 
sinus rhythm at enrollment, but a history of AF 
was not an exclusion criterion. Patients were 
randomized in a 1:1 ratio to conventional or triple-
-site resynchronization therapy with implantable 
cardioverter-defibrillator (ICD). The enrollment 
was accomplished in January 2010, and 100 con-
secutive patients were included.
Two patients were excluded up to 3 months 
after randomization due to lung cancer in one and 
alcohol abuse and non-compliance in the second, 
data of these patients were not further analyzed. 
Two other patients in whom the implantation of 
resynchronization systems failed and who received 
ICD without device-based monitoring capabilities, 
were also excluded. Finally, data from 96 patients 
were used for the analysis.
The study protocol has been approved by 
a local Ethics Committee and complies with the 
Declaration of Helsinki. The trial has been regis-
tered on the Clinical Trials website (www.clinical-
trials.gov) and has been assigned with the clinical 
trial no NCT 00814840. Written informed consent 
was obtained from all study participants.
Collection and analysis of clinical data
Data on potential adverse events were col-
lected during planned appointments (1 week, 1, 3, 
6 months after implantation and every 6 months 
thereafter) and unscheduled ones throughout the 
whole observation period. They were retrieved 
from patients, relatives, witnesses, attending 
physicians, hospital records, outpatient notes, 
letters, death certificates, device memory, and all 
other available sources. The data obtained were 
subsequently classified by 2 independent experts, 
blinded to patients’ treatment arm.
For the purpose of this analysis major adverse 
cardiovascular event (MACE) was considered 
a composite of hospitalization for heart failure (HF), 
heart transplantation, stroke, inadequate interven-
tion of defibrillator, or any-cause death, whichever 
occurred first.
Arrhythmic data
Pacemakers’ check-up was performed during 
every scheduled and unscheduled appointment. 
The whole memory content, including arrhythmic 
episodes, was downloaded on every visit (includ-
ing post mortem interrogation, if possible). Files 
stored were subsequently converted into a format 
recognizable by commonly used database (Micro-
soft Excel, Microsoft, USA) and analyzed. Every, 
even the shortest AF episode was analyzed in 
this study, no duration cut-off was used to exclude 
short-lasting episodes.
Devices used in the trial (InSync Sentry 7298, 
Medtronic, Minneapolis, USA) detect AF using two 
main criteria: the activation patterns and timing and 
rate in both chambers (classified by an algorithm 
called PR Logic). In each ventricular cycle, the 
device incremented AF evidence count if all of the 
following parameters were identified: (1) atrio-
ventricular pattern typical for a high atrial rate; 
(2) timing consistent with an atrial tachyarrhyth-
mia (atrial activation sensed within 50 ms after or 
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80 ms prior to ventricular activation); (3) greater 
than 1:1 atrio-ventricular conduction.
Once the AF evidence count was greater than 
or equal to 6, the arrhythmia was detected. For 
the purpose of this study, percent of cumulative 
time spent in AF, duration of the longest episode, 
number of episodes, and mean ventricular rate dur-
ing all episodes were calculated within 24 months 
after implantation. Further, these parameters were 
recalculated for the period between implantation 
and the first MACE event.
Appropriateness of every antiarrhythmic 
therapy delivered by defibrillator and stored in 
a device memory was assessed by two independ-
ent reviewers blinded to patients’ treatment arm.
During the trial 17 patients died, in 4 of whom 
CRT-D interrogation was performed post-mortem. 
Median percent of the whole observation covered 
by interrogated devices memory was 100% (inter-
quartile range [IQR] = 0).
Statistical analysis
Normality of distribution was tested with 
Kolgomorov-Smirnov test. The continuous param-
eters were presented as mean ± standard devia-
tion or median ± IQR (depending on parameters’ 
distribution), categorical variables as numbers and 
percentages. Comparison between the groups were 
performed with the c2, t-Student or Mann-Whitney 
U tests, as appropriate.
Multivariate Cox regression models were con-
structed to assess independent predictive impact 
of time spent in arrhythmia, duration of the longest 
episode and number of episodes. Receiver-oper-
ating characteristics was used to calculate cut-off 
with the most balanced sensitivity and specificity 
of prognosticator. Generalized linear model for 
binomial data, with logit link function were used to 
test for interactions. All statistical analyses were 
performed using the Statistica software package 




The average age in the whole group was 
61.5 years ± IQR 13.5, 22% of patients were female 
and 15% presented with NYHA class IV. Ischemic 
etiology was present in 60% of cases. The median 
LVEF was 24 ± 4.5% and QRS duration was 
169 ± 30.5 ms before CRT-D implantation. At en-
rollment 13% of patients had previously diagnosed 
AF, while 87% had no history of AF.
Arrhythmia incidence in patients  
with and without arrhythmic history
From among 13 patients with known AF before 
resynchronization, at least one episode of this ar-
rhythmia occurred in 92% subjects within 2 years 
after implantation. In this group, the cumulative 
percent of time spent in arrhythmia was higher 
(median 0.21% ± IQR 7.7 vs. 0.0001% ± 0.05), 
durations of the longest episodes were longer 
(18.5 ± 17.3 h vs. 0.02 ± 1.9 h; both p < 0.001) 
and the number of AF episodes was greater (23 ± 
± 83 vs. 2 ± 31, p < 0.05) than in patients without 
arrhythmic history (Fig. 1A–C). Adjusting for age, 
previously diagnosed AF posed a 2.75-time higher 
probability of experiencing this arrhythmia within 
further observation (p = 0.002; Fig. 1D).
On the other hand, from among 83 subjects in 
whom no AF was recognized prior to CRT, as many 
as 66% patients developed also this arrhythmia 
within the next 24 months. Of those, 36% had at 
least 1 episode lasting > 15 min, in 20% the long-
est arrhythmic event lasted > 5.5 h, and 13% had 
> 100 episodes. In 3% of patients the arrhythmia 
progressed from paroxysmal to persistent form (vs. 
15% of subjects with AF history; p < 0.05). Assign-
ment to the study group did not affect cumulative 
proportion of time in AF (median in the triple-site 
group = 0.0002 vs. the conventional group = 
= 0.008%), duration of the longest episode (0.02 vs. 
0.51 h) or number of episodes (3 vs. 3, all p = NS).
Factors associated with propensity to AF
Patients with and without AF history had distinct 
baseline characteristics. Subjects with previously 
diagnosed arrhythmia had significantly (all p < 0.05) 
more frequently conduction block with non-left bun-
dle branch block morphology in ECG (23% vs. 6%) 
and more compromised renal function (median serum 
creatinine 107 µmol/L vs. 91 µmol/L) than patients 
without AF prior to CRT (Table 1). On the contrary, 
considering only subjects without AF history, no 
baseline features indicated those who developed 
eventually this arrhythmia within further follow-up. 
The only differences between those with AF and free 
of AF were, in fact, confined to more frequent use of 
loop diuretics (98% vs. 85%) and oral anticoagulants 
among patients with arrhythmia (Table 1).
AF and outcome
Considering the whole study population, pa-
tients who experienced at least one device-de-
tected AF episode did not differ (all p = NS) from 
arrhythmia-free group with respect to 24-month 
mortality (18% vs. 17%), rates of non-fatal HF 
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hospitalizations (31% vs. 17%), or strokes (1.5% 
vs. 3%). However, the rates of inappropriate 
interventions of automatic defibrillator (61% vs. 
27%), as well as the incidence of combined MACE 
events (69% vs. 41%; both p < 0.05) were both 
significantly higher in the arrhythmic group. Nine 
percent of AF patients underwent catheter abla-
tion of atrioventricular junction within 24-month 
observation (vs. 0% in AF free group).
Prognostic impact of cumulative time spent 
in arrhythmia, longest episode duration 
and the number of episodes
Cumulative percent of time spent in AF and 
duration of the longest AF episode, but not the 
number of episodes were independent predictors 
of mortality (Table 2). Every additional percent 
of time spent in AF increased the risk of death 
by 5% (adjusted hazard ratio [HR] 1.05 ± 95% 
confidence interval [CI] 1.01–1.10; p = 0.03). In 
turn, every increase in episode duration by 1 h 
was associated with 6% increase in mortality risk 
(HR 1.06; 95% CI 1.01–1.12; p = 0.03) (Table 2). 
Cumulative percent of time in arrhythmia, but not 
episode duration and number of episodes, was also 
independent predictor of MACE. The MACE-risk 
increased by 3% with any additional percent of 
time spent in AF (Table 3). One percent of time 
in AF had 35% sensitivity and 91% specificity in 
predicting future death. The optimally balanced 
cut-off for time in arrhythmia to predict mortality 
was 6.14% (sensitivity 29%, specificity 97%), and 
to predict MACE was 0.005% (sensitivity 60%, 
specificity 76%).
Figure 1. Atrial fibrillation (AF) incidence and burden in patients with and without arrhythmic history; A. Monthly and 
cumulative percent of time spent in AF. Boxes denote means, whiskers denote standard deviations; B. Duration of the 
longest arrhythmia episode; C. Number of arrhythmic episodes; D. Curves of cumulative survival without AF within 
2 years after cardiac resynchronization (adjusted for age); CI — confidence interval; HR — hazard ratio.
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Factors modifying the prognostic role  
of arrhythmia burden
Prognostic impact of percent of time spent in 
AF was influenced by mean ventricular rate during 
arrhythmia (p for interaction = 0.002; Pearson’s 
c2 for goodness of fit 64.9; degrees of freedom 65). 
In patients with low ventricular rate during 
arrhythmia (≤ 98/min) and higher than median 
percent of time (> 0.03%) spent in AF mortality 
was 18%, while in those with lower than median 
arrhythmia burden death rate events were only 3%. 
On the other hand, in subjects with high ventricular 
rate during AF, mortality was less dependent on 
arrhythmia burden and significant (6%) even in low 
arrhythmia burden (Fig. 2).
Opposite to ventricular rate, prognostic im-
portance of arrhythmia load was independent from 
CHADS2 scores (p for interaction = 0.61). Similarly, 
prognostic effect was independent neither from 
CRT burden (p = 0.08), nor from previous ablation 
of atrioventricular node (p = 0.06). Also, assign-
ment to the treatment arm (triple-site vs. standard 
CRT) did not affect prognostic impact of time spent 
in AF (p for interaction = 0.33).
Discussion
Several studies analyzed device-stored data 
to assess the incidence of AF in CRT patients 
[5, 8–17]. However, in the great majority of them 
Table 1. Baseline characteristics of groups with and without atrial fibrillation.









Age [year] 62 (16) 61 (13) 61 (15) 62 (13)
Female 2 (15) 19 (23) 12 (22) 7 (25)
NYHA class 3 (0) 3 (0) 3 (0) 3 (0)
Ischemic etiology 7 (54) 51 (61) 33 (60) 18 (64)
Arterial hypertension 10 (77) 52 (63) 36 (65) 16 (57)
Diabetes mellitus 4 (31) 30 (36) 21 (38) 9 (32)
QRS width [ms] 167 (26) 170 (33) 172 (31) 162.5 (43)
LBBB 10 (77) 78 (94)* 52 (94) 26 (93)
CHADS2 score 3 (2) 3 (2) 3 (2) 3 (2)
LVEF [%] 25 (7) 24 (4) 24 (4) 23.5 (5)
LVESV [mL] 152 (78) 202 (102) 202 (113) 191.5 (89)
LVEDV [mL] 212 (87) 268 (120) 268 (135) 260.5 (113)
Left atrium diameter [mm] 44 (10) 44 (10) 46 (11) 41 (8)
Mitral incompetence grade 1 (2) 2 (2) 2 (2) 2 (2)
Creatinine [µmol/L] 107 (46) 91 (31)* 88 (36) 93.5 (30)
NT-proBNP [pg/mL] 1,408.5 (4,287) 1,597 (2,855) 1,441 (2,249) 2,054 (3,794)
Medication at discharge: 
Beta-blocker 13 (100) 82 (99) 54 (98) 28 (100)
ACEI/ARB 13 (100) 82 (99) 54 (98) 28 (100)
Aldosterone antagonist 12 (92) 80 (96) 54 (98) 26 (93)
Loop diuretic 11 (85) 78 (94) 54 (98) 24 (86)+
Digoxin 2 (15) 7 (8) 5 (9) 2 (7)
Amiodarone 2 (15) 4 (5) 4 (7) 0
Oral anticoagulant 11 (85) 9 (11)* 8 (14) 1 (4)
Oral anticoagulants at 24 months# 9 (90) 24 (35)* 23 (50) 1 (4)+
Continuous data are presented as median (interquartile range), dichotomic parameters as number (percent); *p < 0.05 vs. group with AF  
history; +p < 0.05 vs. group with AF during follow-up; #79 patients survived the 24-month period: 10 with and 69 without AF history prior  
to cardiac resynchronization therapy. Among the latter group 46 developed arrhythmia within further follow-up, 23 remained AF-free; ACEI — 
inhi bitor of angiotensinogen converting enzyme; AF — atrial fibrillation; ARB — angiotensin receptor blocker; FU — follow-up; LBBB — left 
bundle branch block; LVEDV — left ventricular end-diastolic volume; LVEF — left ventricular ejection fraction; LVESV — left ventricular  
end-systolic volume; NT-proBNP — N-terminal propeptide of B-type natriuretic peptide; NYHA — New York Heart Association
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monitoring periods were short, ranging from 3 to 
13 months. To our knowledge, in only 2 studies 
device-collected arrhythmic data were gathered 
for over 2 years. In MADIT-CRT substudy, patients 
were monitored for the average of 2.9 years and AF 
incidence within this period ranged from 3% to 9% 
[8]. However, this trial included only patients with 
less advanced HF (NYHA class I/II). In the study by 
Borleffs et al. [9], 25% out of 223 CRT recipients 
developed AF within 32 months. This study in turn 
excluded patients with previous AF history, who 
constitute the majority of subjects developing this 
arrhythmia within further observation [10].
Our data show that when monitoring CRT pa-
tients for 2 years and analyzing every AF episode, 
arrhythmia incidence among patients with previ-
ous arrhythmic history is 92%. This indicates that 
almost every patient with AF-history still does have 
arrhythmia after CRT implantation. These findings 
stay in line with a previous report suggesting that 
resynchronization does not reduce AF incidence 
among patients with prior arrhythmia [10]. This 
finding can also potentially explain higher mortal-
ity risk among CRT recipients with AF history [3, 
18]. Unexpectedly, at least one AF episode could 
also be found in as many as 66% of patients without 
previous arrhythmic history. To our knowledge, the 
incidence of AF in our study has been the greatest 
reported to date (70% of all study patients). Longer 
follow-up and inclusion of every, even the shortest 
AF episode (10% had the longest AF episode ≤ 30 s), 
are the possible explanations for differences be-
tween our data and other reports. Virtually all 
previously published studies used some duration 
Table 2. Multivariate Cox regression models for prediction of mortality.
Variable HR (95% CI) P
Model 1
Age [year] 0.97 (0.91–1.03) 0.36
Ischemic etiology 1.91 (0.58–6.32) 0.29
LBBB 1.20 (0.14–10.14) 0.86
LVEF [%]* 1.11 (0.96–1.27) 0.15
Serum creatinine (10 µmol/L)* 0.96 (0.84–1.10) 0.60
NT-proBNP (100 pg/mL)* 1.01 (1.0–1.02) 0.01
QRS width (10 ms)* 0.83 (0.66–1.05) 0.12
Percent of time spent in AF [%] 1.05 (1.01–1.10) 0.03
Model 2
Age [year] 0.99 (0.93–1.05) 0.72
Ischemic etiology 1.63 (0.48–5.48) 0.43
LBBB 1.12 (0.13–9.64) 0.92
LVEF [%]* 1.07 (0.93–1.22) 0.34
Serum creatinine (10 µmol/L)* 0.98 (0.86–1.12) 0.78
NT-proBNP (100 pg/mL)* 1.01 (1.0–1.02) 0.01
QRS width (10 ms)* 0.80 (0.63–1.03) 0.08
Duration of the longest AF episode [h] 1.06 (1.01–1.12) 0.03
Model 3
Age [year] 0.97 (0.91–1.04) 0.40
Ischemic etiology 1.76 (0.52–5.97) 0.36
LBBB 1.71 (0.20–14.45) 0.62
LVEF [%]* 1.09 (0.95–1.25) 0.21
Serum creatinine (10 µmol/L)* 1.06 (0.95–1.19) 0.30
NT-proBNP (100 pg/mL)* 1.01 (1.00–1.02) 0.01
QRS width (10 ms)* 0.87 (0.70–1.09) 0.23
Number of AF episodes [n] 0.99 (0.99–1.0) 0.42
*Baseline (preoperative) values; AF — atrial fibrillation; CI — confidence interval; HR — hazard ratio; LBBB — left bundle branch block; LVEF — 
left ventricular ejection fraction; NT-proBNP — N-terminal propeptide of B-type natriuretic peptide; NYHA — New York Heart Association
272 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 3
and stroke, and forecasts future AF in pacemaker 
patients. In ASSERT Trial [20], presence of AF 
episode of > 6 min was associated with 2.5-fold 
higher risk of stroke or systemic embolism in 
patients with pacemakers or ICD. TRENDS Trial 
[21] included subgroup of CRT patients, but no data 
were recalculated specifically for this subgroup. 
TRENDS investigators [21] found that in subjects 
with pacemaker, ICD or CRT who present with 
≥ 1 stroke risk factor, daily AF cumulative burden of 
≥ 5.5 h within 30 days doubles the risk of stroke.
Contrary to the aforementioned trials, in 
our approach, arrhythmia load was treated as 
a continuous, rather than a dichotomized variable. 
Additionally, various arrhythmia characteristics 
were assessed to identify the most prognostically 
important ones. We found that irrespective of the 
number of episodes, only percent of time spent in 
Table 3. Multivariate Cox regression models for prediction of major adverse cardiovascular events.
Variable HR (95% CI) P
Model 1
Age [year] 0.99 (0.96–1.03) 0.88
Ischemic etiology 0.57 (0.32–1.0) 0.05
LBBB 0.68 (0.27–1.72) 0.41
LVEF [%]* 1.01 (0.94–1.07) 0.87
Serum creatinine (10 µmol/L)* 1.06 (0.97–1.15) 0.19
NT-proBNP (100 pg/mL)* 1.01 (1.0–1.01) 0.03
QRS width (10 ms)* 0.92 (0.3–1.03) 0.15
Percent of time spent in AF [%] 1.03 (1.01–1.07) 0.03
Model 2
Age [year] 0.99 (0.96–1.02) 0.86
Ischemic etiology 0.57 (0.33–1.0) 0.05
LBBB 0.69 (0.27–1.77) 0.45
LVEF [%]* 0.99 (0.93–1.06) 0.86
Serum creatinine (10 µmol/L)* 1.05 (0.97–1.14) 0.22
NT-proBNP (100 pg/mL)* 1.01 (1.0–1.01) 0.04
QRS width (10 ms)* 0.91 (0.81–1.02) 0.09
Duration of the longest AF episode [h] 1.02 (0.99–1.06) 0.12
Model 3
Age [year] 0.99 (0.96–1.03) 0.87
Ischemic etiology 0.62 (0.35–1.09) 0.09
LBBB 0.63 (0.25–1.58) 0.33
LVEF [%]* 0.99 (0.93–1.06) 0.75
Serum creatinine (10 µmol/L)* 1.05 (0.97–1.14) 0.20
NT-proBNP (100 pg/mL)* 1.01 (1.0–1.01) 0.03
QRS width (10 ms)* 0.93 (0.83–1.03) 0.15
Number of AF episodes [n] 1.0 (0.99–1.01) 0.34
Abbreviations as in Table 2.
cut-offs to detect arrhythmia. However, the use of 
cut-points to diagnose AF can be confusing. Assum-
ing that > 10 min burden/day is needed to detect 
arrhythmia, a hypothetical patient with daily AF 
load of 9 min would be classified by investigators 
as having no arrhythmia at all, while in reality, he 
would spent 0.6% of time (2.3 days every year) 
in AF.
Some of the prior studies attempted to iden-
tify association between some specific level of 
AF burden and further prognosis in patients with 
pacemakers and ICD [19–21]. However, not only 
the analyzed indices differed between various 
studies (cumulative burden, specific duration of 
an episode), but also pre-specified cut-points were 
divergent. MOST investigators [19] found that 
device-detected episode of atrial high rate lasting 
> 5 min predisposes to death, composite of death 
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AF had significant and independent prognostic role 
in CRT recipients. Duration of the longest episode 
predicted also the risk of death. Each additional 
percent in arrhythmia was moderately sensitive 
(35%), but highly specific (91%) in predicting mor-
tality, increasing its risk by 5%. Of note, as little as 
0.005% of time spent in AF showed reasonable sen-
sitivity and specificity in predicting MACE (mainly 
HF hospitalizations and defibrillator therapy). As 
opposed to duration of the longest episode or cu-
mulative AF burden, percent of time in arrhythmia 
seems to be a more universal parameter, which may 
reflect better a time-varying risk factor associated 
with AF. AF-related risk does not probably remain 
stable, but increases with time in patients with pro-
gression to permanent AF, and declines in subject 
free of AF for several months (what is mirrored by 
percent of time in arrhythmia). However, duration 
of the longest episode or cumulative AF burden 
can only increase (or, at best remain stable). What 
is more, cumulative arrhythmia burden and the 
longest episode duration are both hard to compare 
between patients with different observation times.
Our data indicate that prognostic impact of 
time in arrhythmia can be seen only in patients 
with lower ventricular rates, but is less important 
in the group of patients with uncontrolled rates 
during AF. This underscores previously reported 
importance of high ventricular rates during AF, 
effect of which can overwhelm the prognostic im-
pact of high arrhythmia burden [22]. Our results 
indicate that impact of various features of AF may 
vary in HF patients, depending on ventricular 
rate. In subjects in whom AF conducts with high 
ventricular rates, arrhythmia load is probably less 
important, as even short AF episodes with high 
ventricular rates can evoke HF decompensation 
or inappropriate defibrillator therapy. By contrast, 
patients with slow ventricular rates during AF usu-
ally remain hemodynamically stable during short 
episodes. In this group, the clinical manifestation of 
arrhythmia seems to be more time-dependent and 
sufficiently high AF load is probably needed before 
all the repercussions of irregular heart rate, loss 
of “atrial kick”, thromboembolism and other AF 
consequences become apparent. However, these 
hypotheses need to be verified by further stud-
ies. On the other hand, time spent in AF exerted 
its prognostic effect independently from baseline 
CHADS2 scores. This finding is at odds with data 
by Botto et al. [23] who showed that arrhythmia 
burden acts as a prognosticator only in patients 
with intermediate (1–2 CHADS2 points), but not in 
high- or low-risk groups. Yet, our group included 
no patients with CHADS2 0 points (all of them had 
HF), and majority of them could be classified as 
belonging to the intermediate risk group. What is 
probably the most unexpected finding in our study 
is that the percent of time spent in AF acted unfa-
vorably independently from CRT pacing burden and 
prior ablation of atrioventricular node. This result 
suggests that even in patients with high CRT pac-
ing burden, or in those who underwent ablation of 
atrioventricular node, high percent of time spent 
in AF poses unfavorable prognosis. It corresponds 
with earlier data on independent detrimental role 
played by AF in CRT recipients and provokes to 
further attempt to verify the hypothesis, if aggres-
sive rhythm control would be more beneficial than 
rate control in this group [24–28].
Limitations of the study
The study group was relatively small which 
could have led to underestimation of some impor-
tant predictors. Resynchronization devices used 
in the trial did not store intracardiac electrograms 
during AF, therefore it was impossible to verify 
the correctness of the devices’ classification of de-
tected episodes. In fact, some of the episodes could 
have been misdetected due to sensing problems, 
electrical noise, etc. However, despite of missed 
verification of appropriateness in MOST Trial, 
device-detected atrial high rate episodes carried 
unfavorable prognosis.
Figure 2. Predictive value of time spent in atrial fibrilla-
tion (AF) depending on heart rate (HR) during arrhyth-
mia. Patients were dichotomized with respect to median 
values of two parameters: ventricular rate during AF 
(median for whole study population 98/min), and me-
dian cumulative percent of time spent in arrhythmia 
(0.03%). Influence of arrhythmia burden was marked 
more in patients with slower heart rates.
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Conclusions
As many as 7 out of 10 patients had AF within 
2 years after CRT-D implantation, including two-
thirds of subjects without prior history of AF. No 
baseline features were helpful in predicting who 
would develop AF de novo. Cumulative percent 
of time spent in AF and duration of the longest 
episode, but not the number of AF episodes had 
significant and independent impact on further 
outcomes in CRT-patients. Prognostic impact of 
arrhythmia burden was marked only in patients 
with slow ventricular response, but was independ-
ent from CHADS2 scores, percent of biventricular 
pacing and prior nodal ablation.
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